BioNotebook: Seattle Genetics/AbbVie, Auspex, Flexion, Ironwood
This article was originally published in Scrip
Executive Summary
AbbVie extends Seattle Genetics collaboration; Auspex raises $35m; Flexion files for $86m IPO; and Ironwood makes 10% jobs cut.
You may also be interested in...
Seattle Genetics Looking To Improve, Replace Standards Of Care
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.